Advertisement

Topics

Cellerant Therapeutics, Inc. Company Profile

19:15 EDT 18th September 2018 | BioPortfolio

Embryonic Stem Cells are derived from early-stage embryos before mature organs and tissues have developed. Embryonic stem cells have the greatest potential for both self-renewal (creating large numbers of stem cells) and differentiation into many different types of mature cells (bone, muscle, blood, brain, etc.)

Location

1531 Industrial Road
San Carlos
California
94070
United States of America

Contact

Phone: 650-232-2122
Fax: 650-232-5495
Email: info@cellerant.com


News Articles [721 Associated News Articles listed on BioPortfolio]

Cellerant Therapeutics, Inc. Announces FDA Grants Regenerative Medicine Advanced Therapy (RMAT) ...

Read more...

Cellerant Therapeutics, Inc. Announces FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation for Romyelocel-L to Prevent Infections During Neutropenia

RMAT designation confers similar advantages as breakthrough therapy designation Cellerant Therapeutics, Inc., a clinical-stage company developing innovative i...

Cellerant Therapeutics, Inc. Publishes Preclinical Data Highlighting Potential of its CLL1-Targeting Antibody-Drug Conjugate to Treat Acute Myeloid Leukemia

Cellerant Therapeutics, Inc., a clinical-stage company developing innovative immunotherapies for hematologic malignancies and other blood-related disorders, announced the publicat...

Cellerant Therapeutics, Inc. to Present Results of Phase 2 Clinical Trial of CLT-008 at American Society of Clinical Oncology (ASCO) 2018 Annual Meeting and European Hematology Association (EHA) 23rd Congress

Cellerant Therapeutics, Inc., a clinical-stage company developing innovative immunotherapies for hematologic malignancies and other blood-related disorders, today announced that i...

Cellerant Therapeutics, Inc. Presents Phase 2 Results Showing CLT-008 Significantly Reduces Risk of Infections in AML Patients Undergoing Standard Induction Chemotherapy

– Addressing serious neutropenia side effect may allow wider use of “7+3” induction chemotherapy – Presented at European Hematology Association (EHA) 23rd ...

Cellerant Therapeutics, Inc. CLT-008 Phase 2 Results Show Significant Reduction in Infections and Days in Hospital in Severely Neutropenic AML Patients

Results presented at American Society of Clinical Oncology (ASCO) 2018 Annual Meeting Cellerant Therapeutics, Inc., a clinical-stage company developing innovative immun...

Cellerant Therapeutics Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 13042018] Prices from USD $250

SummaryCellerant Therapeutics Inc Cellerant develops novel immunotherapies for oncology and bloodrelated disorders. Its lead product, CLT008, is a myeloid progenitor cell therapy which is in Phase 2 c...

Cellerant Therapeutics Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27022018] Prices from USD $250

SummaryCellerant Therapeutics Inc Cellerant develops novel immunotherapies for oncology and bloodrelated disorders. Its lead product, CLT008, is a myeloid progenitor cell therapy which is in Phase 2 c...

PubMed Articles [435 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Eyes on New Product Development: Preclinical Research.

Clinical Trials [153 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1254 Associated Companies listed on BioPortfolio]

Cellerant Therapeutics Inc.

Cellerant Therapeutics is a clinical stage biotechnology company focused on the regulation of the hematopoietic (blood-forming) system. The Company is developing human stem cell a...

Cellerant Therapeutics, Inc.

Embryonic Stem Cells are derived from early-stage embryos before mature organs and tissues have developed. Embryonic stem cells have the greatest potential for both self-renewal (creating large number...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

More Information about "Cellerant Therapeutics, Inc." on BioPortfolio

We have published hundreds of Cellerant Therapeutics, Inc. news stories on BioPortfolio along with dozens of Cellerant Therapeutics, Inc. Clinical Trials and PubMed Articles about Cellerant Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cellerant Therapeutics, Inc. Companies in our database. You can also find out about relevant Cellerant Therapeutics, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...

Osteoporosis
Osteoporosis is a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in women following menopause and often leading to curvature of the spine from vertebral collapse. Follow and track&n...

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...


Corporate Database Quicklinks



Searches Linking to this Company Record